Cart
sales@molnova.com
RU 59063
CAS No. 155180-53-3
RU 59063( —— )
Catalog No. M27328 CAS No. 155180-53-3
RU 59063 is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 208 | In Stock |
|
| 5MG | 192 | In Stock |
|
| 10MG | 283 | In Stock |
|
| 25MG | 452 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 848 | In Stock |
|
| 200MG | 1107 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRU 59063
-
NoteResearch use only, not for human use.
-
Brief DescriptionRU 59063 is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.
-
DescriptionRU 59063 is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorVHL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number155180-53-3
-
Formula Weight385.41
-
Molecular FormulaC17H18F3N3O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1(C)N(CCCCO)C(=S)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang, Huibin., Et al. Bifunctional molecule based on VHL ligand induced BET degradation as well as preparation and application thereof. CN106749513A.
molnova catalog
related products
-
Bifluranol
Bifluranol (BX341) has anti-androgenic activity and has shown significant anti-prostatic activity in in vivo studies for the treatment of benign prostatic hyperplasia (BPH).
-
LGD-4033
A novel nonsteroidal, oral selective androgen receptor modulator (SARM), binds androgen receptor with high affinity (Ki=1 nM) and selectivity.
-
JNJ63576253
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
